Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30434996 | 1.00 | PDE3B (0.47) | PDE3BPDE3AKMT2ACYP11B1CYP11B2 | |
| SCHEMBL10153730 | 0.83 | PDE3B (0.45) | PDE3BPDE3AKMT2AGRM4MEN1 | |
| SCHEMBL13780087 | 0.78 | KMO (0.58) | PDE3BPDE3AKMT2AMEN1KMO | |
| SCHEMBL10075480 | 0.77 | MAPT (0.59) | KMT2AMEN1MAPTPOLBHTT | |
| SCHEMBL280110 | 0.76 | TSHR (0.58) | PDE3BPDE3AKMT2AMEN1POLB | |
| SCHEMBL10075619 | 0.76 | MAPT (0.62) | MAPTPOLBTP53TSHR | |
| SCHEMBL10075472 | 0.76 | ALDH1A1 (0.57) | KMT2AMEN1GPR55MAPTPOLB | |
| SCHEMBL3173782 | 0.76 | PKM (0.57) | KMT2AMEN1TP53HTT | |
| SCHEMBL3332098 | 0.75 | PDE3B (0.51) | PDE3BPDE3ACYP11B1CYP11B2GRM4 | |
| SCHEMBL265087 | 0.75 | PDE3B (0.54) | PDE3BPDE3ACYP11B1CYP11B2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023116774-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | 赛诺哈勃药业（成都）有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-11078358-B2 | Curable composition including epoxy resin and curable solid filler | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3661990-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M Innovative Properties Company (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200148878-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M INNOVATIVE PROPERTIES COMPANY | 2020-05-14 | — | — | US | disclosed |
| CN-110997748-A | Curable composition comprising an epoxy resin and a curable solid filler | 3M创新有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019027746-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-02-07 | — | — | WO | disclosed |
| US-9328077-B2 | Bicyclic PKM2 activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-05-03 | — | — | US | disclosed |
| US-9181231-B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | PDK2, PDK1, PDK3 | PDE3B 1079/4885PDE3A 1317/4885KMT2A 423/4885 |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | PCK1, PDK2, PFKP | PDE3B 1470/4885PDE3A 1888/4885KMT2A 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.